High Mobility Group Protein B1 - Drugs In Development, 2021

July 2021 | 57 pages | ID: H28A0CC89A0EEN
Global Markets Direct

Abstracts

High Mobility Group Protein B1 - Drugs In Development, 2021

SUMMARY

According to the recently published report 'High Mobility Group Protein B1 - Drugs In Development, 2021'; High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) pipeline Target constitutes close to 11 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - High mobility group box 1 protein also known as high-mobility group protein 1 (HMG-1) is a protein encoded by the HMGB1 gene.HMGB1 is secreted by immune cells like macrophages, monocytes and dendritic cells through leaderless secretory pathway. Activated macrophages and monocytes secrete HMGB1. The mechanism of inflammation and damage is binding to TLR4, which mediates HMGB1-dependent activation of macrophage cytokine release. Treatment includes antibodies that neutralize HMGB1 protects against damage and tissue injury during arthritis, colitis, ischemia, sepsis, endotoxemia, and systemic lupus erythematosus.

The report 'High Mobility Group Protein B1 - Drugs In Development, 2021' outlays comprehensive information on the High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Cardiovascular, Central Nervous System, Oncology, Gastrointestinal, Dermatology, Musculoskeletal Disorders and Other Diseases which include indications Cerebral Infarction (Brain Infarction), Parkinson's Disease, Sepsis, Traumatic Brain Injury, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Brain (Head) Trauma, Cardiomyopathy, Chronic Liver Disease, Dilated Cardiomyopathy, Epidermolysis Bullosa, Epilepsy, Hepatitis B, Hepatitis C, Influenzavirus A Infections, Ischemic Cardiomyopathy, Knee Osteoarthritis, Liver Cirrhosis, Liver Diseases, Non-Alcoholic Steatohepatitis (NASH), Solid Tumor and Stroke.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1)
• The report reviews High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics and enlists all their major and minor projects
• The report assesses High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Overview
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Companies Involved in Therapeutics Development
Afecta Pharmaceuticals Inc
Affibody AB
Chimerix Inc
Kalivir Inc
Shionogi & Co Ltd
TheraSource LLC
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Drug Profiles
ABY-047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AFX-2101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dociparstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit HMGB1 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JH-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit HMGB1 for Influenza A Infections and Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant High Mobility Group Protein B1 Replacement for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit HMGB1 for Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
redasemtide trifluoroacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSA-521 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VET-4H1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Dormant Products
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Product Development Milestones
Featured News & Press Releases
Feb 25, 2021: Chimerix reports promising topline results from first cohort of a randomized COVID-19 trial with DSTAT
Feb 25, 2021: Chimerix reports promising topline results from first cohort of a randomized COVID-19 trial with DSTAT
Apr 29, 2020: Chimerix announces initiation of a phase 2/3 study of DSTAT in acute lung injury for patients with severe COVID-19
Dec 10, 2019: Chimerix presents updated results from phase 2 clinical trial of DSTAT in refractory myelodysplastic syndrome and acute myeloid leukemia at American Society of Hematology Annual Meeting
Jun 04, 2018: Cantex Pharmaceuticals Announces That Clinical Trial Data For CX-01 In Refractory Acute Myeloid Leukemia And Myelodysplastic Syndrome Will Be Presented At The 2018 ASCO Annual Meeting
Mar 12, 2018: Publication in Blood Advances Reports that the Combination of Cantex Pharmaceuticals CX-01 with Chemotherapy for the Treatment of Acute Myeloid Leukemia Showed Encouraging Complete Remission Rates and Rapid Platelet Count Recovery
Jan 03, 2018: Cantex Pharmaceuticals Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia
Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia
Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01
May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting
Feb 09, 2005: ParinGenix Gets FDA Approval of IND for PGX-100
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Afecta Pharmaceuticals Inc, 2021
Pipeline by Affibody AB, 2021
Pipeline by Chimerix Inc, 2021
Pipeline by Kalivir Inc, 2021
Pipeline by Shionogi & Co Ltd, 2021
Pipeline by TheraSource LLC, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021